510(k) Report

510(k) · Cleared

Cleared

Haemonetics Cell Saver Elite/Elite+ Autotransfusion System (CSE-E-US/CSE-EW-US)

K221722510(k) TraditionalCleared Nov 15, 2022154-day reviewClass II21 CFR 868.5830

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Haemonetics Corporation · CAC Apparatus, Autotransfusion

Cleared on Nov 15, 2022 as substantially equivalent to K162423 (Haemonetics Corporation, 2017) after a 154-day review. Its family tree reaches back 6 generations to 1994.

Decided
Nov 15, 2022
Review
154 days
Class
Class II
Product code
CAC
Recalls
None
Predicates
1

Its longest line of descent runs back 6 generations to K932890 (1994). No later device cites it as a predicate yet.

  1. Root · 6 generations backK932890 Cell Saver 5 SystemHaemonetics Corp. · 1994 · Recalled
  2. 5 generations backK014083 Haemonetics Cell Saver 5 Autologous Blood Recovery SystemHaemonetics Corp. · 2002 · Recalled
  3. 4 generations backK101907 Haemonetics Cell Saver Elite Autotransfusion SystemHaemonetics Corp. · 2010 · Recalled
  4. 3 generations backK120586 Cell Saver EliteHaemonetics Corp. · 2012
  5. 2 generations backK160197 Haemonetics Cell Saver Elite Autotransfusion SystemHaemonetics Corporation · 2016
  6. 1 generation backK162423 Haemonetics Cell Saver Elite/Elite+ Autotransfusion SystemHaemonetics Corporation · 2017
  7. This deviceK221722 Haemonetics Cell Saver Elite/Elite+ Autotransfusion System…Haemonetics Corporation · 2022
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−6K932890Cell Saver 5 SystemHaemonetics Corp.199413
−5K014083Haemonetics Cell Saver 5 Autologous Blood Recovery SystemHaemonetics Corp.20023
−4K101907Haemonetics Cell Saver Elite Autotransfusion SystemHaemonetics Corp.20106
−3K120586Cell Saver EliteHaemonetics Corp.2012—
−2K160197Haemonetics Cell Saver Elite Autotransfusion SystemHaemonetics Corporation2016—
−1K162423Haemonetics Cell Saver Elite/Elite+ Autotransfusion SystemHaemonetics Corporation2017—
0 (this device)K221722Haemonetics Cell Saver Elite/Elite+ Autotransfusion System (CSE-E-US/CSE-EW-US)Haemonetics Corporation2022—
FIG. 1 — Lineage of K221722, 1994–2022Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in CAC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new CAC device

  1. #1 K240426 Aventus Clot Management Systemscore 11.2 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K162423Haemonetics Cell Saver Elite/Elite+ Autotransfusion System
Summary page 4
…transfusion Device Classification Name: Autotransfusion Apparatus Regulation Number: 21 CFR 868.5830 Product Code: CAC Device Class: 2 510k Number: K162423 Reference Device Information: Trade Name: Medtronic autoLog IQ Autotransfusion System Common Name: Autotransfus…
Haemonetics Corporation2017—
†K181954autoLog IQ Autotransfusion SystemMedtronic Perfusion Systems2018—
†K131553XTRASorin Group Deutschland GmbH2014—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 28 years and passes through 2 companies; a new generation was cleared every 5.9 years on median.
  • 3 of the 6 ancestors have a recall of any class.

How does its category compare?

All CAC devices

CAC Apparatus, Autotransfusion: FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.

FDA decisions per year · CAC

3in 2024

2008: 12010: 42011: 22012: 32013: 12014: 32016: 22017: 12018: 22019: 12020: 12021: 42022: 12023: 22024: 3
2007high 4 (2010) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CAC

91in 2024

2010: 123 days median2012: 90 days median2014: 269 days median2021: 155 days median2024: 91 days median
2007high 269 (2014) · low 90 (2012)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · CAC

7in 2023

2007: 12008: 52009: 252010: 32011: 32013: 92017: 22018: 22019: 232023: 7, 2 Class I
2007high 25 (2009) · low 0 (2012)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · CAC

128in 2025

2007: 352008: 122009: 682010: 1152011: 9392012: 2492013: 1532014: 902015: 872016: 732017: 882018: 872019: 642020: 1082021: 732022: 652023: 392024: 1292025: 128
2007high 939 (2011) · low 12 (2008)2025

MAUDE reports naming product code CAC, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—135
20081—512
20090—2568
201041233115
20112—3939
20123900249
20131—9153
20143269090
20150—087
20162—073
20171—288
20182—287
20191—2364
20201—0108
20214155073
20221—065
20232—7 (2)39
20243910129
20250—0128
20260—0—

What is it indicated for?

The Haemonetics® Cell Saver® Elite/Elite®+ Autotransfusion System and its related accessory components are intended for use to recover blood shed during or subsequent to an operation or as a result of trauma, processing the blood by a centrifugation and washing procedure, and pumping the processed red blood cells to a product bag. The intended use of the Sequestration Protocol is to collect an autologous, preoperative, platelet rich plasma product for reinfusion to the same patient within the recommended time guidelines of the American Association of Blood Banks (AABB), 9th Edition.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K221722: Haemonetics Cell Saver Elite/Elite+ Autotransfusion System (CSE-E-US/CSE-EW-US).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K221722

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026